Status:
ENROLLING_BY_INVITATION
QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Collaborating Sponsors:
Centre Antoine Lacassagne
Conditions:
Solid Tumor
Eligibility:
All Genders
Brief Summary
"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on ...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic ;
- no standard or curative treatment available;
- non-opposition of the patient collected.
Exclusion
- multiple cancer patient;
- ECOG Scale of Performance Status (PS) ≥2
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04762862
Start Date
February 1 2021
End Date
December 31 2026
Last Update
April 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice
Nice, France, 06000